(0.06%) 5 190.91 points
(0.19%) 38 957 points
(0.00%) 16 333 points
(0.41%) $78.70
(0.41%) $2.22
(0.03%) $2 324.80
(0.49%) $27.68
(-0.44%) $984.05
(0.08%) $0.930
(0.03%) $10.90
(0.13%) $0.800
(0.65%) $92.03
@ $9.92
जारी किया गया: 15 Feb 2024 @ 02:28
वापसी: -39.72%
पिछला सिग्नल: Feb 14 - 00:03
पिछला सिग्नल:
वापसी: 2.06 %
Live Chart Being Loaded With Signals
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments...
Stats | |
---|---|
आज की मात्रा | 50 358.00 |
औसत मात्रा | 365 755 |
बाजार मूल्य | 261.35M |
EPS | $0 ( 2024-05-07 ) |
अगली कमाई की तारीख | ( $-0.0600 ) 2024-08-05 |
Last Dividend | $1.000 ( 2010-01-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.20 |
ATR14 | $0.0200 (0.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Zaderej Karen L. | Buy | 84 847 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 975 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 166 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 500 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 086 | Common Stock |
INSIDER POWER |
---|
41.80 |
Last 98 transactions |
Buy: 1 200 055 | Sell: 468 598 |
मात्रा सहसंबंध
AxoGen Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
WRAP | 0.915 |
WDAY | 0.914 |
EA | 0.869 |
GTEC | 0.865 |
CVLG | 0.859 |
SFET | 0.857 |
CNET | 0.853 |
SMIT | 0.852 |
FATP | 0.848 |
AHPI | 0.848 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
SHYF | -0.915 |
RGLD | -0.91 |
UBFO | -0.902 |
MTRX | -0.899 |
ICUI | -0.897 |
TKNO | -0.893 |
IPKW | -0.892 |
STRA | -0.891 |
VRTS | -0.891 |
SGII | -0.889 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
AxoGen Inc सहसंबंध - मुद्रा/वस्त्र
AxoGen Inc वित्तीय
Annual | 2023 |
राजस्व: | $159.01M |
सकल लाभ: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2023 |
राजस्व: | $159.01M |
सकल लाभ: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2022 |
राजस्व: | $138.58M |
सकल लाभ: | $114.44M (82.58 %) |
EPS: | $-0.650 |
FY | 2021 |
राजस्व: | $127.36M |
सकल लाभ: | $104.43M (81.99 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
AxoGen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0417 | 1992-07-10 |
Last Dividend | $1.000 | 2010-01-27 |
Next Dividend | $0 | N/A |
Payout Date | 2010-02-12 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.102 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 0.965 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1992 | $0.0417 | 0.45% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0.0600 | 4.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $1.000 | 24.10% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.130 | 1.500 | -2.60 | -3.90 | [0 - 0.5] |
returnOnAssetsTTM | -0.114 | 1.200 | -3.80 | -4.56 | [0 - 0.3] |
returnOnEquityTTM | -0.222 | 1.500 | -3.58 | -5.36 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.09 | 0.800 | 2.43 | 1.946 | [0.8 - 2.5] |
cashRatioTTM | 0.947 | 1.500 | 5.85 | 8.78 | [0.2 - 2] |
debtRatioTTM | 0.260 | -1.500 | 5.67 | -8.50 | [0 - 0.6] |
interestCoverageTTM | -34.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.244 | 2.00 | -0.0814 | -0.163 | [0 - 30] |
freeCashFlowPerShareTTM | -0.515 | 2.00 | -0.257 | -0.515 | [0 - 20] |
debtEquityRatioTTM | 0.520 | -1.500 | 7.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.797 | 1.000 | 0.0450 | 0.0450 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.114 | 1.000 | -4.28 | -4.28 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.218 | 1.000 | -2.32 | -2.32 | [0.2 - 2] |
assetTurnoverTTM | 0.878 | 0.800 | 7.48 | 5.99 | [0.5 - 2] |
Total Score | 0.965 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -11.85 | 1.000 | -1.298 | 0 | [1 - 100] |
returnOnEquityTTM | -0.222 | 2.50 | -2.30 | -5.36 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.515 | 2.00 | -0.172 | -0.515 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.244 | 2.00 | -0.0814 | -0.163 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.348 | 1.500 | -5.65 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0645 | 1.000 | -4.11 | 0 | [0.1 - 0.5] |
Total Score | -2.01 |
AxoGen Inc
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं